Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	24.91B -26.4%
Revenue (ttm)	11.71B -0.3%
Net Income	1.96B -6.1%
EPS	2.20 -3.9%
Shares Out	887.91M
PE Ratio	13.94
Forward PE	12.76
Dividend	1.43 (4.66%)
Ex-Dividend Date	Jun 16, 2026

Volume	6,264,069
Open	30.61
Previous Close	30.73
Day's Range	30.50 - 31.13
52-Week Range	27.67 - 42.58
Beta	0.14
Analysts	Buy
Price Target	38.41 (+24.91%)
Earnings Date	Aug 21, 2026

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2025, SHE:000513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Analyst Summary

According to 5 analysts, the average rating for 000513 stock is "Buy." The 12-month stock price target is ¥38.41, which is an increase of 24.91% from the latest price.

Price Target

¥38.41

(24.91% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error